Raras
Buscar doenças, sintomas, genes...
Doença mieloproliferativa crônica
ORPHA:98274CID-10 · D47.1DOENÇA RARA

Distúrbio clonal de células-tronco hematopoéticas, caracterizado pela proliferação na medula óssea de uma ou mais linhagens mieloides (isto é, granulocíticas, eritróides, megacariocíticas e mastócitos). É principalmente uma neoplasia de adultos. (OMS 2008)

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distúrbio clonal de células-tronco hematopoéticas, caracterizado pela proliferação na medula óssea de uma ou mais linhagens mieloides (isto é, granulocíticas, eritróides, megacariocíticas e mastócitos). É principalmente uma neoplasia de adultos. (OMS 2008)

Pesquisas ativas
15 ensaios
2230 total registrados no ClinicalTrials.gov
Publicações científicas
2.873 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
3.07
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D47.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
30 sintomas
🦴
Ossos e articulações
9 sintomas
🫃
Digestivo
6 sintomas
📏
Crescimento
5 sintomas
🫁
Pulmão
5 sintomas
🛡️
Imunológico
3 sintomas

+ 72 sintomas em outras categorias

Características mais comuns

Hipertensão
Sintoma constitucional
Hepatoesplenomegalia
Fadiga fácil
Neoplasia hematológica
Caquexia
144sintomas
Sem dados (144)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 144 características clínicas mais associadas, ordenadas por frequência.

HipertensãoHypertension
Sintoma constitucionalConstitutional symptom
HepatoesplenomegaliaHepatosplenomegaly
Fadiga fácilEasy fatigability
Neoplasia hematológicaHematological neoplasm

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.873PubMed
Últimos 10 anos200publicações
Pico2025129 papers
Linha do tempo
2026Hoje · 2026🧪 1975Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

51 genes identificados com associação a esta condição.

MLLT10Protein AF-10Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. In cells, binding to unmodified histone H3 regulates DOT1L functions including histone H3 'Lys-79' dimethylation (H3K79me2) and gene activation (PubMed:26439302)

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.9 TPM
Cervix Ectocervix
32.3 TPM
Útero
31.2 TPM
Ovário
30.5 TPM
Bladder
29.2 TPM
OUTRAS DOENÇAS (2)
acute myeloid leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:16063UniProt:P55197
RPN1Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1Candidate gene tested inAltamente restrito
FUNÇÃO

Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:31831667). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates

LOCALIZAÇÃO

Endoplasmic reticulum membraneMelanosome

VIAS BIOLÓGICAS (6)
Maturation of spike proteinAsparagine N-linked glycosylationPD-L1(CD274) glycosylation and translocation to plasma membraneMaturation of DENV proteinsRegulation of CDH1 posttranslational processing and trafficking to plasma membrane
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
226.2 TPM
Pulmão
150.2 TPM
Tireoide
142.3 TPM
Cervix Endocervix
125.5 TPM
Útero
119.5 TPM
OUTRAS DOENÇAS (1)
acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)
HGNC:10381UniProt:P04843
DEKProtein DEKCandidate gene tested inTolerante
FUNÇÃO

Involved in chromatin organization

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsTranscriptional regulation of granulopoiesisB-WICH complex positively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
163.2 TPM
Fibroblastos
118.3 TPM
Tireoide
98.6 TPM
Artéria tibial
94.1 TPM
Útero
92.9 TPM
OUTRAS DOENÇAS (1)
acute myeloid leukemia with t(6;9)(p23;q34)
HGNC:2768UniProt:P35659
TBL1XR1F-box-like/WD repeat-containing protein TBL1XR1Candidate gene tested inAltamente restrito
FUNÇÃO

F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
PPARA activates gene expressionActivation of gene expression by SREBF (SREBP)Transcriptional regulation of white adipocyte differentiationRORA,B,C and NR1D1 (REV-ERBA) regulate gene expressionExpression of BMAL (ARNTL), CLOCK, and NPAS2
MECANISMO DE DOENÇA

Pierpont syndrome

An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
51.9 TPM
Cervix Ectocervix
38.1 TPM
Cervix Endocervix
37.9 TPM
Fibroblastos
36.7 TPM
Aorta
35.9 TPM
OUTRAS DOENÇAS (3)
Pierpont syndromeintellectual disability, autosomal dominant 41acute promyelocytic leukemia
HGNC:29529UniProt:Q9BZK7
NABP1SOSS complex subunit B2Candidate gene tested inTolerante
FUNÇÃO

Component of the SOSS complex, a multiprotein complex that functions downstream of the MRN complex to promote DNA repair and G2/M checkpoint. In the SOSS complex, acts as a sensor of single-stranded DNA that binds to single-stranded DNA, in particular to polypyrimidines. The SOSS complex associates with DNA lesions and influences diverse endpoints in the cellular DNA damage response including cell-cycle checkpoint activation, recombinational repair and maintenance of genomic stability. Required

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
RNA polymerase II transcribes snRNA genes
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
53.0 TPM
Baço
33.5 TPM
Pulmão
22.1 TPM
Sangue
19.2 TPM
Intestino delgado
16.3 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:26232UniProt:Q96AH0
PMLProtein PMLCandidate gene tested inRestrito
FUNÇÃO

Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Inhibits EIF4E-mediated mRNA nuclear export by reducing EIF4E affinity for the 5' 7-methylguanosine

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmCytoplasmNucleus, PML bodyNucleus, nucleolusEndoplasmic reticulum membraneEarly endosome membrane

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
55.3 TPM
Útero
50.0 TPM
Cervix Ectocervix
49.5 TPM
Pulmão
49.1 TPM
Mama
49.1 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:9113UniProt:P29590
MRTFAMyocardin-related transcription factor ACandidate gene tested inAltamente restrito
FUNÇÃO

Transcription coactivator that associates with the serum response factor (SRF) transcription factor to control expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration (PubMed:26224645). The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. MRTFA binds G-actin via its RPEL repeats, regulating activity of the MRTFA-

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
RHO GTPases Activate Formins
OUTRAS DOENÇAS (3)
immunodeficiency 66megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)immune deficiency due to impaired neutrophil phagocytosis and migration
HGNC:14334UniProt:Q969V6
STAT5BSignal transducer and activator of transcription 5BCandidate gene tested inAltamente restrito
FUNÇÃO

Carries out a dual function: signal transduction and activation of transcription (PubMed:29844444). Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription. Positively regulates hematopoietic/erythroid differentiation

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Prolactin receptor signalingInterleukin-2 signalingErythropoietin activates STAT5Interleukin-7 signalingInterleukin-3, Interleukin-5 and GM-CSF signaling
MECANISMO DE DOENÇA

Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive

An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
155.5 TPM
Sangue
138.5 TPM
Fallopian Tube
134.4 TPM
Ovário
129.2 TPM
Cervix Ectocervix
113.3 TPM
OUTRAS DOENÇAS (3)
growth hormone insensitivity with immune dysregulation 1, autosomal recessivegrowth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominantacute promyelocytic leukemia
HGNC:11367UniProt:P51692
RUNX1T1Protein CBFA2T1Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:10688654, PubMed:12559562, PubMed:15203199). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Can repress transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion protein freq

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
37.2 TPM
Cerebelo
28.5 TPM
Nervo tibial
14.2 TPM
Cervix Ectocervix
12.1 TPM
Cervix Endocervix
11.9 TPM
OUTRAS DOENÇAS (1)
acute myeloid leukemia with t(8;21)(q22;q22) translocation
HGNC:1535UniProt:Q06455
CBFBCore-binding factor subunit betaCandidate gene tested inAltamente restrito
FUNÇÃO

Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site o

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
RUNX3 Regulates Immune Response and Cell MigrationRegulation of RUNX3 expression and activityRUNX3 regulates p14-ARFRUNX3 regulates RUNX1-mediated transcriptionTranscriptional regulation by RUNX2
OUTRAS DOENÇAS (2)
cleidocranial dysplasia 2acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
HGNC:1539UniProt:Q13951
MYH11Myosin-11Candidate gene tested inAltamente restrito
FUNÇÃO

Muscle contraction

LOCALIZAÇÃO

Melanosome

VIAS BIOLÓGICAS (8)
RHO GTPases activate PAKsRHO GTPases Activate ROCKsRHO GTPases activate PKNsRHO GTPases activate CITSema4D induced cell migration and growth-cone collapse
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
8417.6 TPM
Cólon sigmoide
7101.3 TPM
Esôfago - Junção
6634.6 TPM
Artéria tibial
5189.9 TPM
Bladder
3106.5 TPM
OUTRAS DOENÇAS (7)
megacystis-microcolon-intestinal hypoperistalsis syndrome 2visceral myopathy 2aortic aneurysm, familial thoracic 4acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
HGNC:7569UniProt:P35749
BCORBCL-6 corepressorCandidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Microphthalmia, syndromic, 2

A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

OUTRAS DOENÇAS (4)
microphthalmia, syndromic 2acute promyelocytic leukemiaclear cell sarcoma of kidneymicrophthalmia, Lenz type
HGNC:20893UniProt:Q6W2J9
TGM6Protein-glutamine gamma-glutamyltransferase 6Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Spinocerebellar ataxia 35

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA35 patients commonly show upper limb involvement and torticollis. There is no cognitive impairment.

EXPRESSÃO TECIDUAL(Não detectado)
Cervix Ectocervix
0.0 TPM
Testículo
0.0 TPM
Skin Sun Exposed Lower leg
0.0 TPM
Skin Not Sun Exposed Suprapubic
0.0 TPM
Esôfago - Mucosa
0.0 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
spinocerebellar ataxia type 35inherited acute myeloid leukemia
HGNC:16255UniProt:O95932
RBM15RNA-binding protein 15Candidate gene tested inAltamente restrito
FUNÇÃO

RNA-binding protein that acts as a key regulator of N6-methyladenosine (m6A) methylation of RNAs, thereby regulating different processes, such as hematopoietic cell homeostasis, alternative splicing of mRNAs and X chromosome inactivation mediated by Xist RNA (PubMed:27602518). Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (By similarity). Plays a

LOCALIZAÇÃO

Nucleus speckleNucleus, nucleoplasmNucleus envelopeNucleus membrane

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.8 TPM
Testículo
12.1 TPM
Fibroblastos
7.6 TPM
Baço
6.8 TPM
Pulmão
6.5 TPM
OUTRAS DOENÇAS (1)
megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
HGNC:14959UniProt:Q96T37
KMT2AHistone-lysine N-methyltransferase 2ACandidate gene tested inAltamente restrito
FUNÇÃO

Histone methyltransferase that plays an essential role in early development and hematopoiesis (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:26886794). Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac) (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:2

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (5)
Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genesRUNX1 regulates transcription of genes involved in differentiation of HSCsPhosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promotersThe CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complexTranscriptional regulation of granulopoiesis
MECANISMO DE DOENÇA

Wiedemann-Steiner syndrome

A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
34.8 TPM
Cérebro - Hemisfério cerebelar
32.5 TPM
Ovário
26.9 TPM
Artéria tibial
25.5 TPM
Útero
24.7 TPM
OUTRAS DOENÇAS (7)
Wiedemann-Steiner syndromemixed phenotype acute leukemia with t(9;22)(q34.1;q11.2)mixed phenotype acute leukemia with t(v;11q23.3)B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
HGNC:7132UniProt:Q03164
KAT6AHistone acetyltransferase KAT6ACandidate gene tested inAltamente restrito
FUNÇÃO

Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro) (PubMed:11742995, PubMed:11965546). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity (PubMed:11965546). May act as a transcriptional coactivator for RUNX1 and RUNX2 (PubMed:12771199). Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML (PubMed:23431171). May play a role in leukemogenic gene transcription

LOCALIZAÇÃO

NucleusNucleus, nucleolusNucleus, nucleoplasmNucleus, PML body

VIAS BIOLÓGICAS (2)
Regulation of TP53 Activity through AcetylationHATs acetylate histones
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
28.6 TPM
Útero
26.8 TPM
Cervix Ectocervix
25.7 TPM
Skin Sun Exposed Lower leg
25.1 TPM
Nervo tibial
24.6 TPM
OUTRAS DOENÇAS (2)
autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndromeacute myeloid leukemia with t(8;16)(p11;p13) translocation
HGNC:13013UniProt:Q92794
CREBBPCREB-binding proteinCandidate gene tested inAltamente restrito
FUNÇÃO

Acetylates histones, giving a specific tag for transcriptional activation (PubMed:21131905, PubMed:24616510). Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively) (PubMed:21131905). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1 (PubMed:10490106, PubMed:11154691, PubMed:12738767, PubMed:12929931, PubMed:24207024, PubMed:28790157, PubMed:30540930, PubMed:35675826, PubMed:9707565). Binds specifically to ph

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
SARS-CoV-2 activates/modulates innate and adaptive immune responses
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
53.4 TPM
Ovário
49.6 TPM
Cervix Endocervix
48.1 TPM
Cerebelo
45.0 TPM
Artéria tibial
41.8 TPM
OUTRAS DOENÇAS (5)
Menke-Hennekam syndrome 1Rubinstein-Taybi syndrome due to CREBBP mutationsMenke-Hennekam syndromeacute myeloid leukemia with t(8;16)(p11;p13) translocation
HGNC:2348UniProt:Q92793
ZBTB16Zinc finger and BTB domain-containing protein 16Candidate gene tested inAltamente restrito
FUNÇÃO

Acts as a transcriptional repressor (PubMed:10688654, PubMed:24359566). Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters (PubMed:10688654). May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:145283

LOCALIZAÇÃO

NucleusNucleus, nuclear body

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Skeletal defects, genital hypoplasia, and impaired intellectual development

A disorder characterized by intellectual disability, craniofacial dysmorphism, microcephaly and short stature. Additional features include absence of the thumbs, hypoplasia of the radii and ulnae, additional vertebrae and ribs, retarded bone age and genital hypoplasia.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
112.3 TPM
Aorta
71.4 TPM
Tecido adiposo
61.8 TPM
Nervo tibial
57.0 TPM
Artéria coronária
54.9 TPM
OUTRAS DOENÇAS (2)
acute promyelocytic leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:12930UniProt:Q05516
NUMA1Nuclear mitotic apparatus protein 1Candidate gene tested inAltamente restrito
FUNÇÃO

Microtubule (MT)-binding protein that plays a role in the formation and maintenance of the spindle poles and the alignement and the segregation of chromosomes during mitotic cell division (PubMed:17172455, PubMed:19255246, PubMed:24996901, PubMed:26195665, PubMed:27462074, PubMed:7769006). Functions to tether the minus ends of MTs at the spindle poles, which is critical for the establishment and maintenance of the spindle poles (PubMed:11956313, PubMed:12445386). Plays a role in the establishmen

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus matrixChromosomeCytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindle poleCytoplasm, cell cortexCell membraneLateral cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Mitotic Prophase
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
145.1 TPM
Cervix Endocervix
144.4 TPM
Útero
143.8 TPM
Ovário
130.7 TPM
Próstata
130.3 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:8059UniProt:Q14980
FIP1L1Pre-mRNA 3'-end-processing factor FIP1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the cleavage and polyadenylation specificity factor (CPSF) complex that plays a key role in pre-mRNA 3'-end formation, recognizing the AAUAAA signal sequence and interacting with poly(A) polymerase and other factors to bring about cleavage and poly(A) addition. FIP1L1 contributes to poly(A) site recognition and stimulates poly(A) addition. Binds to U-rich RNA sequence elements surrounding the poly(A) site. May act to tether poly(A) polymerase to the CPSF complex

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
mRNA 3'-end processingDengue Virus-Host InteractionsTransport of Mature mRNA Derived from an Intronless TranscriptProcessing of Intronless Pre-mRNAsRNA Polymerase II Transcription Termination
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.7 TPM
Testículo
78.1 TPM
Fibroblastos
70.5 TPM
Ovário
55.4 TPM
Cervix Endocervix
47.6 TPM
OUTRAS DOENÇAS (3)
acute promyelocytic leukemiaprimary hypereosinophilic syndromechronic eosinophilic leukemia
HGNC:19124UniProt:Q6UN15
STAT3Signal transducer and activator of transcription 3Candidate gene tested inAltamente restrito
FUNÇÃO

Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18242580, PubMed:18782771, PubMed:22306293, PubMed:23084476, PubMed:28262505, PubMed:32929201, PubMed:38404237). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:15653507, Pu

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Interleukin-20 family signalingDownstream signal transductionInterleukin-15 signalingSignaling by SCF-KITInterleukin-9 signaling
MECANISMO DE DOENÇA

Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections

A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
173.0 TPM
Artéria tibial
145.7 TPM
Aorta
144.8 TPM
Adipose Visceral Omentum
140.2 TPM
Fallopian Tube
136.9 TPM
OUTRAS DOENÇAS (7)
hyper-IgE recurrent infection syndrome 1, autosomal dominantSTAT3-related early-onset multisystem autoimmune diseasebreast implant-associated anaplastic large cell lymphomaacute promyelocytic leukemia
HGNC:11364UniProt:P40763
ERCC6L2DNA excision repair protein ERCC-6-like 2Candidate gene tested inTolerante
FUNÇÃO

Promotes double-strand break (DSB) end-joining and facilitates programmed recombination by controlling how DNA ends are joined in a spatially oriented manner during repair (By similarity). Also plays a role in DNA repair by restricting DNA end resection in double strand break (DSB) repair (PubMed:24507776, PubMed:37014751). Facilitates replication of complex DNA regions and regulates the maintenance of chromatin structure (PubMed:37014751)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeMitochondrionChromosome, centromere

MECANISMO DE DOENÇA

Bone marrow failure syndrome 2

An autosomal recessive disorder characterized by trilineage bone marrow failure, bone marrow hypocellularity, learning difficulties, and microcephaly. Insufficient hematopoiesis results in peripheral blood cytopenias, affecting myeloid, erythroid and megakaryocyte lines. Cutaneous features and increased chromosome breakage are not features.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
8.8 TPM
Cervix Ectocervix
7.6 TPM
Cervix Endocervix
7.4 TPM
Ovário
7.2 TPM
Útero
6.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
pancytopenia-developmental delay syndromeinherited acute myeloid leukemia
HGNC:26922UniProt:Q5T890
CBFA2T3Transcriptional corepressor CBFA2T3Candidate gene tested inTolerante
FUNÇÃO

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:12559562, PubMed:15203199, PubMed:16966434, PubMed:18456661). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Reduces the protein levels and stability of the transcriptinal regulator HIF1A; interacts with EGLN1 and promotes the HIF1A prolyl hydroxylation-de

LOCALIZAÇÃO

NucleusNucleus, nucleolusNucleus, nucleoplasmGolgi apparatus membrane

OUTRAS DOENÇAS (1)
acute megakaryoblastic leukemia without down syndrome
HGNC:1537UniProt:O75081
PDGFRBPlatelet-derived growth factor receptor betaCandidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth

LOCALIZAÇÃO

Cell membraneCytoplasmic vesicleLysosome lumen

VIAS BIOLÓGICAS (1)
Signaling by PDGF
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
398.1 TPM
Cervix Endocervix
353.6 TPM
Artéria tibial
346.2 TPM
Tecido adiposo
303.2 TPM
Artéria coronária
277.8 TPM
OUTRAS DOENÇAS (10)
myofibromatosis, infantile, 1acroosteolysis-keloid-like lesions-premature aging syndromebasal ganglia calcification, idiopathic, 4ocular pterygium-digital keloid dysplasia syndrome
HGNC:8804UniProt:P09619
TET2Methylcytosine dioxygenase TET2Candidate gene tested inTolerante
FUNÇÃO

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (2)
TET1,2,3 and TDG demethylate DNASpecification of primordial germ cells
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
12.3 TPM
Cervix Ectocervix
10.8 TPM
Vagina
10.4 TPM
Skin Not Sun Exposed Suprapubic
10.3 TPM
Skin Sun Exposed Lower leg
10.2 TPM
OUTRAS DOENÇAS (11)
myelodysplastic syndromeimmunodeficiency 75acute myeloid leukemia with multilineage dysplasiamyelodysplastic syndrome with ring sideroblasts
HGNC:25941UniProt:Q6N021
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
PRKAR1AcAMP-dependent protein kinase type I-alpha regulatory subunitCandidate gene tested inAltamente restrito
FUNÇÃO

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (10)
PKA activationGPER1 signalingCREB1 phosphorylation through the activation of Adenylate CyclaseDARPP-32 eventsHigh laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
MECANISMO DE DOENÇA

Carney complex 1

CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
152.7 TPM
Ovário
151.5 TPM
Aorta
138.6 TPM
Útero
138.3 TPM
Tecido adiposo
129.4 TPM
OUTRAS DOENÇAS (9)
familial atrial myxomapigmented nodular adrenocortical disease, primary, 1Acrodysostosis 1 with or without hormone resistanceCarney complex, type 1
HGNC:9388UniProt:P10644
BCRBreakpoint cluster region proteinCandidate gene tested inRestrito
FUNÇÃO

Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:17116687, PubMed:1903516, PubMed:7479768). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modul

LOCALIZAÇÃO

Postsynaptic densityCell projection, dendritic spineCell projection, axonSynapse

VIAS BIOLÓGICAS (7)
RAC3 GTPase cycleRHOB GTPase cycleRAC1 GTPase cycleRAC2 GTPase cycleCDC42 GTPase cycle
MECANISMO DE DOENÇA

Leukemia, chronic myeloid

A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.

OUTRAS DOENÇAS (4)
chronic myelogenous leukemia, BCR-ABL1 positivechromosome 22q11.2 deletion syndrome, distalB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)precursor T-cell acute lymphoblastic leukemia
HGNC:1014UniProt:P11274
LPPLipoma-preferred partnerDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a structural role at sites of cell adhesion in maintaining cell shape and motility. In addition to these structural functions, it may also be implicated in signaling events and activation of gene transcription. May be involved in signal transduction from cell adhesion sites to the nucleus allowing successful integration of signals arising from soluble factors and cell-cell adhesion sites. Also suggested to serve as a scaffold protein upon which distinct protein complexes are assembled i

LOCALIZAÇÃO

NucleusCytoplasmCell junctionCell membrane

VIAS BIOLÓGICAS (1)
Lysosphingolipid and LPA receptors
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
190.8 TPM
Esôfago - Muscular
147.3 TPM
Aorta
128.2 TPM
Esôfago - Junção
116.1 TPM
Cólon sigmoide
98.3 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
acute myeloid leukemia
HGNC:HGNC:6679UniProt:Q93052
CBLE3 ubiquitin-protein ligase CBLDisease-causing germline mutation(s) inRestrito
FUNÇÃO

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567, PubMed:40101708). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, Pu

LOCALIZAÇÃO

CytoplasmCell membraneCell projection, ciliumGolgi apparatus

VIAS BIOLÓGICAS (10)
TGF-beta receptor signaling activates SMADsPTK6 Regulates RTKs and Their Effectors AKT1 and DOK1Spry regulation of FGF signalingEGFR downregulationNegative regulation of MET activity
MECANISMO DE DOENÇA

Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia

A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.

OUTRAS DOENÇAS (4)
CBL-related disorderjuvenile myelomonocytic leukemiaNoonan syndromeaggressive systemic mastocytosis
HGNC:1541UniProt:P22681
SRCProto-oncogene tyrosine-protein kinase SrcDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors (PubMed:34234773). Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosi

LOCALIZAÇÃO

Cell membraneMitochondrion inner membraneNucleusCytoplasm, cytoskeletonCytoplasm, perinuclear regionCell junction, focal adhesionCell junction

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsG alpha (i) signalling eventsSignaling by CSF1 (M-CSF) in myeloid cells
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
59.3 TPM
Testículo
55.3 TPM
Bladder
52.0 TPM
Próstata
51.5 TPM
Cervix Ectocervix
49.8 TPM
OUTRAS DOENÇAS (2)
colorectal cancerthrombocytopenia 6
HGNC:11283UniProt:P12931
DNMT3ADNA (cytosine-5)-methyltransferase 3ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development (PubMed:12138111, PubMed:16357870, PubMed:30478443). DNA methylation is coordinated with methylation of histones (PubMed:12138111, PubMed:16357870, PubMed:30478443). It modifies DNA in a non-processive manner and also methylates non-CpG sites (PubMed:12138111, PubMed:16357870, PubMed:30478443). May preferentially methylate DNA linker between 2 nucleosomal cores and i

LOCALIZAÇÃO

NucleusChromosomeCytoplasm

VIAS BIOLÓGICAS (6)
RMTs methylate histone argininesDefective pyroptosisPRC2 methylates histones and DNADNA methylationRegulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
MECANISMO DE DOENÇA

Tatton-Brown-Rahman syndrome

An overgrowth syndrome characterized by a distinctive facial appearance, tall stature and intellectual disability. Facial gestalt is characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures. Less common features include atrial septal defects, seizures, umbilical hernia, and scoliosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
20.9 TPM
Cérebro - Hemisfério cerebelar
18.9 TPM
Pituitária
18.8 TPM
Ovário
18.3 TPM
Linfócitos
15.5 TPM
OUTRAS DOENÇAS (5)
Tatton-Brown-Rahman overgrowth syndromeHeyn-Sproul-Jackson syndromeacute myeloid leukemiaacute myeloid leukemia with multilineage dysplasia
HGNC:2978UniProt:Q9Y6K1
PICALMPhosphatidylinositol-binding clathrin assembly proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytoplasmic adapter protein that plays a critical role in clathrin-mediated endocytosis which is important in processes such as internalization of cell receptors, synaptic transmission or removal of apoptotic cells. Recruits AP-2 and attaches clathrin triskelions to the cytoplasmic side of plasma membrane leading to clathrin-coated vesicles (CCVs) assembly (PubMed:10436022, PubMed:16262731, PubMed:27574975). Furthermore, regulates clathrin-coated vesicle size and maturation by directly sensing a

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pitGolgi apparatusCytoplasmic vesicle, clathrin-coated vesicleNucleus

VIAS BIOLÓGICAS (3)
Clathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosisRND3 GTPase cycle
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
255.3 TPM
Tecido adiposo
210.5 TPM
Aorta
194.4 TPM
Artéria coronária
182.9 TPM
Nervo tibial
175.8 TPM
OUTRAS DOENÇAS (2)
acute myeloid leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:15514UniProt:Q13492
RUNX1Runt-related transcription factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, inc

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Pre-NOTCH Transcription and TranslationRegulation of RUNX1 Expression and ActivityRUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX3 regulates p14-ARFRUNX1 regulates transcription of genes involved in differentiation of keratinocytes
EXPRESSÃO TECIDUAL(Ubíquo)
Glândula salivar
31.0 TPM
Fibroblastos
22.0 TPM
Pulmão
18.9 TPM
Mama
18.8 TPM
Nervo tibial
13.1 TPM
OUTRAS DOENÇAS (6)
acute myeloid leukemiahereditary thrombocytopenia and hematologic cancer predisposition syndromehereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1acute myeloid leukemia with t(8;21)(q22;q22) translocation
HGNC:10471UniProt:Q01196
CALRCalreticulinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER (PubMed:7876246). Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export (PubMed:11149926). Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation

LOCALIZAÇÃO

Endoplasmic reticulum lumenCytoplasm, cytosolSecreted, extracellular space, extracellular matrixCell surfaceSarcoplasmic reticulum lumenCytoplasmic vesicle, secretory vesicle, Cortical granuleCytolytic granule

VIAS BIOLÓGICAS (2)
Antigen Presentation: Folding, assembly and peptide loading of class I MHCER-Phagosome pathway
OUTRAS DOENÇAS (4)
thrombocythemia 1primary myelofibrosisessential thrombocythemiaBudd-Chiari syndrome
HGNC:1455UniProt:P27797
NF1NeurofibrominDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity

LOCALIZAÇÃO

NucleusNucleus, nucleolusCell membrane

VIAS BIOLÓGICAS (1)
RAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Neurofibromatosis 1

A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.9 TPM
Cérebro - Hemisfério cerebelar
17.1 TPM
Cerebelo
15.3 TPM
Nervo tibial
14.9 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (12)
neurofibromatosis, familial spinalneurofibromatosis type 1juvenile myelomonocytic leukemiaWatson syndrome
HGNC:7765UniProt:P21359
RARARetinoic acid receptor alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor for retinoic acid (PubMed:16417524, PubMed:19850744, PubMed:20215566, PubMed:21152046, PubMed:37478846). Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes (PubMed:21152046, PubMed:28167758, PubMed:37478846). The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (5)
Activation of anterior HOX genes in hindbrain development during early embryogenesisNuclear Receptor transcription pathwayTranscriptional regulation of granulopoiesisTGFBR3 expressionSUMOylation of intracellular receptors
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
83.8 TPM
Pulmão
63.0 TPM
Cervix Endocervix
58.2 TPM
Fallopian Tube
57.2 TPM
Cervix Ectocervix
53.9 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:9864UniProt:P10276
KITMast/stem cell growth factor receptor KitDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulator

LOCALIZAÇÃO

Cell membraneCytoplasm

VIAS BIOLÓGICAS (5)
Developmental Lineage of Mammary Gland Luminal Epithelial CellsDevelopmental Lineage of Mammary Gland Alveolar CellsTFAP2 (AP-2) family regulates transcription of growth factors and their receptorsSignaling by SCF-KITRegulation of KIT signaling
MECANISMO DE DOENÇA

Piebald trait

Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
44.5 TPM
Ovário
36.4 TPM
Esôfago - Junção
35.3 TPM
Cérebro - Hemisfério cerebelar
29.8 TPM
Tireoide
28.1 TPM
OUTRAS DOENÇAS (21)
gastrointestinal stromal tumorcutaneous mastocytosisacute myeloid leukemiapiebaldism
HGNC:6342UniProt:P10721
ABL1Tyrosine-protein kinase ABL1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENA

LOCALIZAÇÃO

Cytoplasm, cytoskeletonNucleusMitochondrionNucleus membrane

VIAS BIOLÓGICAS (1)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
MECANISMO DE DOENÇA

Leukemia, chronic myeloid

A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.

OUTRAS DOENÇAS (4)
chronic myelogenous leukemia, BCR-ABL1 positivecongenital heart defects and skeletal malformations syndromeB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)precursor T-cell acute lymphoblastic leukemia
HGNC:76UniProt:P00519
MPLThrombopoietin receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K (PubMed:15899890, PubMed:37633268). In turn, These signaling cascades lead to the proliferation, survival, and differentiation of megakaryocytes, ultimately leading to increased pla

LOCALIZAÇÃO

Cell membraneGolgi apparatusCell surface

VIAS BIOLÓGICAS (1)
Platelet Aggregation (Plug Formation)
MECANISMO DE DOENÇA

Amegakaryocytic thrombocytopenia, congenital, 1

An autosomal recessive form of congenital amegakaryocytic thrombocytopenia, a hematologic disorder characterized by severe reduction of megakaryocytes and platelets at birth, and evolving into generalized bone marrow aplasia during childhood.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.5 TPM
Ovário
0.7 TPM
Pulmão
0.7 TPM
Nervo tibial
0.6 TPM
Tecido adiposo
0.5 TPM
OUTRAS DOENÇAS (6)
thrombocythemia 2primary myelofibrosiscongenital amegakaryocytic thrombocytopenia 1essential thrombocythemia
HGNC:7217UniProt:P40238
CEBPACCAAT/enhancer-binding protein alphaDisease-causing germline mutation(s) inModerado
FUNÇÃO

Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Crit

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (3)
Transcriptional regulation of granulopoiesisTranscriptional regulation of white adipocyte differentiationMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

OUTRAS DOENÇAS (4)
acute myeloid leukemiainherited acute myeloid leukemiaacute myeloid leukemia with t(8;21)(q22;q22) translocationacute myeloid leukemia with CEBPA somatic mutations
HGNC:1833UniProt:P49715
JAK2Tyrosine-protein kinase JAK2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and

LOCALIZAÇÃO

Endomembrane systemCytoplasmNucleus

VIAS BIOLÓGICAS (10)
Interleukin-20 family signalingRAF activationSignaling downstream of RAS mutantsSignaling by moderate kinase activity BRAF mutantsParadoxical activation of RAF signaling by kinase inactive BRAF
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
68.9 TPM
Aorta
46.9 TPM
Artéria coronária
31.6 TPM
Tecido adiposo
20.8 TPM
Nervo tibial
20.0 TPM
OUTRAS DOENÇAS (9)
thrombocythemia 3acquired polycythemia veraprimary myelofibrosisprimary familial polycythemia due to EPO receptor mutation
HGNC:6192UniProt:O60674
GATA1Erythroid transcription factorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional activator or repressor which serves as a general switch factor for erythroid development (PubMed:35030251). It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS (PubMed:24245781)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX1 regulates transcription of genes involved in differentiation of HSCsFactors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

X-linked dyserythropoietic anemia and thrombocytopenia

Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
25.8 TPM
Pulmão
3.7 TPM
Testículo
3.6 TPM
Baço
1.9 TPM
Pituitária
0.8 TPM
OUTRAS DOENÇAS (10)
transient myeloproliferative syndromethrombocytopenia, X-linked, with or without dyserythropoietic anemiahemolytic anemia due to erythrocyte adenosine deaminase overproductionX-linked dyserythropoetic anemia with abnormal platelets and neutropenia
HGNC:4170UniProt:P15976
PTPN11Tyrosine-protein phosphatase non-receptor type 11Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742426, PubMed:28074573, PubMed:32184441). Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)Spry regulation of FGF signalingRegulation of IFNA/IFNB signalingRegulation of IFNG signalingGPVI-mediated activation cascade
MECANISMO DE DOENÇA

LEOPARD syndrome 1

A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
111.4 TPM
Brain Spinal cord cervical c-1
108.7 TPM
Artéria tibial
90.4 TPM
Substância negra
83.1 TPM
Aorta
73.7 TPM
OUTRAS DOENÇAS (7)
juvenile myelomonocytic leukemiaNoonan syndrome 1metachondromatosisLEOPARD syndrome 1
HGNC:9644UniProt:Q06124
NUP214Nuclear pore complex protein Nup214Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Part of the nuclear pore complex (PubMed:9049309). Has a critical role in nucleocytoplasmic transport (PubMed:31178128). May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex (PubMed:31178128, PubMed:8108440) (Microbial infection) Required for capsid disassembly of the human adenovirus 5 (HadV-5) leading to release of the viral genome to the nucleus (in vitro)

LOCALIZAÇÃO

Nucleus, nuclear pore complex

VIAS BIOLÓGICAS (10)
snRNP AssemblyHCMV Early EventsHCMV Late EventsNEP/NS2 Interacts with the Cellular Export MachineryTransport of Ribonucleoproteins into the Host Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
95.8 TPM
Baço
40.1 TPM
Linfócitos
26.7 TPM
Útero
25.7 TPM
Tireoide
25.3 TPM
OUTRAS DOENÇAS (5)
leukemia, acute lymphocytic, susceptibility to, 1acute myeloid leukemiaacute myeloid leukemia with t(6;9)(p23;q34)precursor T-cell acute lymphoblastic leukemia
HGNC:8064UniProt:P35658
NPM1NucleophosminDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double-stran

LOCALIZAÇÃO

Nucleus, nucleolusNucleus, nucleoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (4)
PKR-mediated signalingTP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertainNuclear import of Rev proteinNuclear events stimulated by ALK signaling in cancer
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1517.5 TPM
Fibroblastos
1222.0 TPM
Ovário
1031.3 TPM
Cervix Endocervix
640.5 TPM
Útero
622.0 TPM
OUTRAS DOENÇAS (8)
acute myeloid leukemiaacute promyelocytic leukemiaacute myeloid leukemia with NPM1 somatic mutationsdyskeratosis congenita
HGNC:7910UniProt:P06748
KRASGTPase KRasDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
SH2B3SH2B adapter protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
Regulation of KIT signalingNegative regulation of FLT3Factors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

Celiac disease 13

A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
56.0 TPM
Linfócitos
43.0 TPM
Pulmão
41.6 TPM
Fibroblastos
37.9 TPM
Adipose Visceral Omentum
34.1 TPM
OUTRAS DOENÇAS (5)
primary myelofibrosisthrombocythemia 1primary familial polycythemia due to EPO receptor mutationgrowth retardation-mild developmental delay-chronic hepatitis syndrome
HGNC:29605UniProt:Q9UQQ2
ARHGAP26Rho GTPase-activating protein 26Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

GTPase-activating protein for RHOA and CDC42. Facilitates mitochondrial quality control by promoting Parkin-mediated recruitment of autophagosomes to damaged mitochondria (PubMed:38081847). Negatively regulates the growth of human parainfluenza virus type 2 by inhibiting hPIV-2-mediated RHOA activation via interaction with two of its viral proteins P and V (PubMed:27512058) Associates with MICAL1 on the endosomal membrane to promote Rab8-Rab10-dependent tubule extension. After dissociation of MI

LOCALIZAÇÃO

Endosome membraneCytoplasmCell junction, focal adhesionCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
RAC3 GTPase cycleRHOJ GTPase cycleRHOB GTPase cycleRAC1 GTPase cycleRHOD GTPase cycle
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

OUTRAS DOENÇAS (1)
juvenile myelomonocytic leukemia
HGNC:HGNC:17073UniProt:Q9UNA1
ETV6Transcription factor ETV6Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Signaling by FLT3 fusion proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
45.0 TPM
Glândula salivar
42.7 TPM
Skin Sun Exposed Lower leg
35.5 TPM
Linfócitos
30.0 TPM
Aorta
29.4 TPM
OUTRAS DOENÇAS (9)
acute myeloid leukemiathrombocytopenia 5B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)obsolete autosomal thrombocytopenia with normal platelets
HGNC:3495UniProt:P41212
FLT3Receptor-type tyrosine-protein kinase FLT3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or

LOCALIZAÇÃO

MembraneEndoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
FLT3 Signaling
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
22.5 TPM
Cerebelo
19.7 TPM
Baço
5.4 TPM
Sangue
3.4 TPM
Brain Spinal cord cervical c-1
3.3 TPM
OUTRAS DOENÇAS (11)
leukemia, acute lymphocytic, susceptibility to, 1acute myeloid leukemiaB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)mixed phenotype acute leukemia with t(v;11q23.3)
HGNC:3765UniProt:P36888

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Reblozyl (LUSPATERCEPT)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

44 variantes patogênicas registradas no ClinVar.

🧬 MLLT10: NM_001195626.3(MLLT10):c.2064-4A>G ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.2064-18G>T ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.1052-10T>A ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.241-4A>G ()
🧬 MLLT10: GRCh37/hg19 10p14-q26.3(chr10:11138692-135427143) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 24 variantes classificadas pelo ClinVar.

12
5
7
Patogênica (50.0%)
VUS (20.8%)
Benigna (29.2%)
VARIANTES MAIS SIGNIFICATIVAS
NOTCH1: NM_017617.5(NOTCH1):c.2296G>A (p.Gly766Ser) [Conflicting classifications of pathogenicity]
ITPKB: NM_002221.4(ITPKB):c.518G>A (p.Arg173His) [Conflicting classifications of pathogenicity]
ITPKB: NM_002221.4(ITPKB):c.267CAGCGGCAG[1] (p.91GSS[1]) [Conflicting classifications of pathogenicity]
PTEN: NM_001304717.5(PTEN):c.140GGC[5] (p.Arg52del) [Likely pathogenic]
PTEN: NM_000314.8(PTEN):c.-326= [Pathogenic]

Vias biológicas (Reactome)

386 vias biológicas associadas aos genes desta condição.

SRP-dependent cotranslational protein targeting to membrane Asparagine N-linked glycosylation Maturation of spike protein Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Maturation of DENV proteins PD-L1(CD274) glycosylation and translocation to plasma membrane B-WICH complex positively regulates rRNA expression Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors Transcriptional regulation of granulopoiesis BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression NOTCH1 Intracellular Domain Regulates Transcription Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HDACs deacetylate histones Notch-HLH transcription pathway Transcriptional regulation of white adipocyte differentiation Regulation of lipid metabolism by PPARalpha Loss of MECP2 binding ability to the NCoR/SMRT complex Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux HCMV Early Events Cytoprotection by HMOX1 Heme signaling MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression RNA polymerase II transcribes snRNA genes SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Regulation of TP53 Activity through Acetylation Interferon gamma signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN localization Dengue virus activates/modulates innate and adaptive immune responses SUMOylation of transcription cofactors RHO GTPases Activate Formins Prolactin receptor signaling Interleukin-7 signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction Signaling by Leptin Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Erythropoietin activates STAT5 STAT5 Activation Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Inactivation of CSF3 (G-CSF) signaling Growth hormone receptor signaling RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Transcriptional regulation by RUNX2 RUNX1 regulates estrogen receptor mediated transcription RUNX1 regulates expression of components of tight junctions RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX1 regulates transcription of genes involved in differentiation of keratinocytes RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known RUNX1 regulates transcription of genes involved in BCR signaling RUNX1 regulates transcription of genes involved in differentiation of myeloid cells RUNX1 regulates transcription of genes involved in interleukin signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity RUNX2 regulates osteoblast differentiation RUNX2 regulates chondrocyte maturation RUNX2 regulates bone development RUNX2 regulates genes involved in cell migration RUNX2 regulates genes involved in differentiation of myeloid cells Regulation of RUNX3 expression and activity RUNX3 Regulates Immune Response and Cell Migration RUNX3 regulates RUNX1-mediated transcription RUNX3 regulates p14-ARF Estrogen-dependent gene expression EPHA-mediated growth cone collapse Sema4D induced cell migration and growth-cone collapse Smooth Muscle Contraction RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases activate PAKs Developmental Lineage of Mammary Gland Myoepithelial Cells PKMTs methylate histone lysines Formation of WDR5-containing histone-modifying complexes Regulation of PD-L1(CD274) transcription Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex HATs acetylate histones Regulation of gene expression by Hypoxia-inducible Factor Pre-NOTCH Transcription and Translation Formation of the beta-catenin:TCF transactivating complex Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Attenuation phase Activation of anterior HOX genes in hindbrain development during early embryogenesis CD209 (DC-SIGN) signaling TP53 Regulates Transcription of Genes Involved in Cytochrome C Release Activation of the TFAP2 (AP-2) family of transcription factors RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation FOXO-mediated transcription of cell death genes Neddylation Antigen processing: Ubiquitination & Proteasome degradation Recruitment of NuMA to mitotic centrosomes Mitotic Prophase Transport of Mature mRNA Derived from an Intronless Transcript mRNA 3'-end processing RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs Signaling by cytosolic PDGFRA and PDGFRB fusion proteins mRNA Polyadenylation Dengue Virus-Host Interactions Interleukin-6 signaling BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Signalling to STAT3 Signaling by ALK Senescence-Associated Secretory Phenotype (SASP) POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Association of TriC/CCT with target proteins during biosynthesis Transcriptional regulation of pluripotent stem cells Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling PTK6 Activates STAT3 MET activates STAT3 Interleukin-35 Signalling Interleukin-37 signaling Interleukin-23 signaling Interleukin-27 signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants PIP3 activates AKT signaling Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TET1,2,3 and TDG demethylate DNA Specification of primordial germ cells Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks TP53 Regulates Transcription of DNA Repair Genes TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PKA activation PKA activation in glucagon signalling DARPP-32 events Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins CREB1 phosphorylation through the activation of Adenylate Cyclase Hedgehog 'off' state GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis ALK mutants bind TKIs Signaling by ALK fusions and activated point mutants Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Signaling by FGFR1 in disease RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle LPPR2 LPPR5 LPPR4(LPPR1-3,5) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling p38MAPK events Signaling by EGFR GAB1 signalosome Regulation of gap junction activity FCGR activation PECAM1 interactions EPH-Ephrin signaling Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins NCAM signaling for neurite out-growth Co-stimulation by CD28 Co-inhibition by CTLA4 Signal regulatory protein family interactions EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 PRC2 methylates histones and DNA RMTs methylate histone arginines SUMOylation of DNA methylation proteins DNA methylation Defective pyroptosis Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Golgi Associated Vesicle Biogenesis RND3 GTPase cycle SLC-mediated transport of organic cations SARS-CoV-1 activates/modulates innate immune responses Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) ER-Phagosome pathway Assembly of Viral Components at the Budding Site Scavenging by Class A Receptors Scavenging by Class F Receptors ATF6 (ATF6-alpha) activates chaperone genes Calnexin/calreticulin cycle Antigen Presentation: Folding, assembly and peptide loading of class I MHC Regulation of RAS by GAPs RAS signaling downstream of NF1 loss-of-function variants Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Signaling by Retinoic Acid TGFBR3 expression TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Cyclin D associated events in G1 FCGR3A-mediated phagocytosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Platelet Aggregation (Plug Formation) MAPK3 (ERK1) activation MAPK1 (ERK2) activation RAF activation IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Regulation of IFNG signaling Signaling by Erythropoietin Interleukin-12 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants PI3K Cascade GPVI-mediated activation cascade Tie2 Signaling Co-inhibition by PD-1 Netrin mediated repulsion signals Platelet sensitization by LDL PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs snRNP Assembly Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins HuR (ELAVL1) binds and stabilizes mRNA SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Deposition of new CENPA-containing nucleosomes at the centromere TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation SARS-CoV-1-host interactions Nuclear events stimulated by ALK signaling in cancer PKR-mediated signaling SOS-mediated signalling Activation of RAS in B cells SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signalling to RAS GRB2 events in EGFR signaling SHC1 events in EGFR signaling GRB2 events in ERBB2 signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation Ca2+ pathway Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation SHC-mediated cascade:FGFR1 SHC-mediated cascade:FGFR2 SHC-mediated cascade:FGFR3 RHOD GTPase cycle RHOQ GTPase cycle RHOJ GTPase cycle Signaling by membrane-tethered fusions of PDGFRA or PDGFRB FLT3 Signaling FLT3 mutants bind TKIs KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants FLT3 signaling through SRC family kinases

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 212
1Fase 13
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 17 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença mieloproliferativa crônica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

9 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

2.230 ensaios clínicos encontrados, 15 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.377 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.377

#1

Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.

Hematology, transfusion and cell therapy2026 Mar 12

Philadelphia-negative myeloproliferative neoplasms are clonal blood disorders characterized by abnormal blood cell production. This study explores the clinical and epidemiological profiles of 111 Ecuadorian patients diagnosed with Philadelphia-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, between 2014 and 2023. Patients were treated in different institutions, with clinical data collected on disease progression, complications, and survival. Polycythemia vera was the most common subtype (45.9%), followed by essential thrombocythemia (42.3%) and primary myelofibrosis (9%). The JAK2 V617F mutation was most prevalent in essential thrombocythemia (53.2%) and polycythemia vera (41.2%). Hydroxyurea, the most widely used treatment, was prescribed to 77% of the patients. Disease progression to myelofibrosis occurred in three polycythemia vera and two essential thrombocythemia cases, meanwhile One case of primary myelofibrosis and one case of myeloproliferative neoplasm, unclassified, progressed to acute myeloid leukemia. Survival rates varied across the cohort; notably, certain patients with polycythemia vera and essential thrombocythemia achieved survival durations of up to 19 years. These results reveal a relatively homogeneous epidemiological profile across the Latin American region and underscore the need for more multicenter studies to better characterize pH- MPNs in Ecuador and the region, to optimize diagnostic and treatment strategies.

#2

Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.

Circulation reports2026 Mar 10

Patients with myeloproliferative neoplasms (MPN) are known to complicate pulmonary hypertension (PH). Half of patients with MPN-associated PH have chronic thromboembolic PH (CTEPH); however, the prevalence, clinical characteristics, and treatment response remain unclear. Nagoya PH registry database was retrospectively analyzed. Of 129 CTEPH patients, 82 were included. Clinical characteristics and treatment response were compared between CTEPH patients with MPN (MPN group) and those without MPN (non-MPN group). As the treatment course at Nagoya University Hospital, medical treatment was initiated before performing balloon pulmonary angioplasty (BPA)/pulmonary endarterectomy (PEA). Right heart catheterization was performed at pre-medication, post-medication, and post-BPA/PEA. Seven patients had concomitant MPN as the underlying cause for CTEPH, accounting for 5.4% (7/129) of CTEPH cases. Baseline clinical characteristics were comparable between the MPN and non-MPN groups. No significant difference was observed in ∆pulmonary vascular resistance (PVR) from baseline to post-medical treatment (-3.59 WU in the MPN group vs. -3.80 WU in the non-MPN group; P=0.67) and baseline to post-BPA/PEA (-6.92 WU in the MPN group vs. -7.60 WU in the non-MPN group; P=0.35). As hemodynamic responses to treatment in CTEPH patients with MPN were comparable with those without MPN, their prognosis may improve with multimodal CTEPH treatment similar to non-MPN cases.

#3

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

The Lancet. Haematology2026 Mar

QuANTUM-First is a randomised phase 3 trial in individuals with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD) positive, showing a survival advantage for quizartinib versus placebo plus standard induction and consolidation chemotherapy with or without transplantation, followed by single-agent maintenance therapy. We evaluated the impact of quizartinib on patient-reported outcomes and health-related quality of life using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire. In this global, multicentre, randomised, placebo-controlled, phase 3 trial, we recruited adults aged 18-75 years, with FLT3-ITD-positive newly diagnosed AML or AML secondary to myelodysplastic syndrome or myeloproliferative neoplasm, and with an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly allocated (1:1) to quizartinib (40 mg/day) or placebo plus standard 7 + 3 induction chemotherapy, and then received standard consolidation chemotherapy with high-dose cytarabine plus quizartinib (40 mg/day) or placebo, allogeneic haematopoietic cell transplantation (allo-HCT), or both, followed by maintenance with single-agent quizartinib (30-60 mg/day) or placebo for up to 36 cycles. Randomisation was managed via an interactive web and voice response system. Patient-reported outcome endpoints, assessed using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, were exploratory and analyses were based on the patient-reported outcome intention-to-treat analysis set. Treatment effects on patient-reported outcomes were assessed using the mixed-effects model for repeated measures, time to sustained improvement, and time until definitive deterioration analyses. A minimal clinically important difference score of 10 or higher for each subscale was defined as clinically meaningful. This trial is registered with ClinicalTrials.gov, NCT02668653, and is completed. Participants were enrolled between Sept 27, 2016, and Aug 14, 2019. Of 539 randomly allocated participants, 509 (278 [55%] female and 231 [45%] male) were included in the patient-reported outcome analysis set, 254 in the quizartinib group and 255 in the placebo group. The overall median follow-up was 39·2 months (IQR 31·9-45·8). Baseline patient-reported outcome scores were similar between groups. The change in global health status and quality of life score (GHS-QoL) from baseline was above the minimal clinically important difference from consolidation onwards in both groups. The treatment difference (quizartinib minus placebo) in change from baseline for GHS-QoL (by mixed-effects model for repeated measures) was -2·0 (95% CI -4·8 to 0·7, nominal p=0·15), indicating no substantial difference between groups, further confirmed by time to sustained improvement (subdistribution hazard ratio [SHR] 1·126 [95% CI 0·904 to 1·403], nominal p=0·28) and time until definitive deterioration (hazard ratio 0·81 [95% CI 0·51 to 1·28], nominal p=0·37) analyses. Longitudinal analyses of the functional and symptom subscales showed no substantially different patterns between groups. For the functional subscales, the SHR ranged from 0·940 to 1·148 (0·737-1·544, nominal p=0·36-0·90). For the symptom subscales, the SHR ranged from 0·965 to 1·407 (0·720-1·989, nominal p=0·28-0·99). The results indicate that quizartinib plus standard chemotherapy prolongs overall survival without adversely affecting patient-reported outcomes and health-related quality of life, with no substantial differences between groups. Future research in real-world settings is warranted to assess the generalisability of these patient-reported outcome results. Daiichi Sankyo.

#4

The function and molecular mechanism of HIF-1α interacted with p-STAT3 in promoting G6PD overexpression in chronic myelogenous leukemia cells.

Cellular signalling2026 Feb 25

Chronic myeloid leukemia (CML) is a malignant myeloproliferative neoplasm originating from hematopoietic stem cells, which substantially contributes to the morbidity and mortality among leukemia patients. Our findings demonstrated that glucose-6-phosphate dehydrogenase (G6PD) is aberrantly overexpressed in CML, where it promotes the proliferation of CML cells and modulates their cell cycle distribution. Furthermore, we observed a positive correlation between G6PD overexpression and the resistance of CML cells to imatinib. Subsequent mechanistic investigations revealed that the complex formed by the interaction of phosphorylated STAT3 (p-STAT3) and hypoxia-inducible factor 1α (HIF-1α) functions as a novel transcriptional regulator of G6PD, thereby driving its increased expression. Collectively, this study provides compelling evidence that strategies directly targeting p-STAT3/HIF-1α-G6PD may represent an effective therapeutic approach to suppress CML cells proliferation and overcome drug resistance, offering new insights into the diagnosis and clinical management of CML patients.

#5

Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026 Mar

Patients with chronic myeloproliferative neoplasms (MPNs) have upregulated renin-angiotensin-aldosteron system in the bone marrow and suffer from debilitating inflammation-linked symptoms. The use of angiotensin-converting enzyme inhibitors (ACEi) has been shown to improve hematocrit control and thrombotic risk in MPNs. Here, we investigated whether ACEi use may also have an impact on disease-related symptoms in MPNs. This cross-sectional two-center study included 100 consecutive MPN patients who fulfilled the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) at the time of study entry. The use of ACEi correlated with older age, presence of JAK2 mutation, prior thrombosis and different cardiovascular risk factors. Patients using ACEi also presented with higher total symptom score (p = 0.002), more abdominal discomfort (p = 0.031), concentration problems (p = 0.050) and bone pains (p = 0.001). To account for baseline variables that may have potentially impacted MPN symptom control, ACEi users and non-users were case-matched in a 1:1 ratio with respect to sex, age, cytoreductive treatment, and cardiovascular risk factors. Again, there were no differences in almost all MPN-SAF items with respect to ACEi use (p > 0.050 for all analyses). The use of ACEi does not seem to mitigate disease-related symptoms in MPNs. Prospective randomized trials are needed to fully elucidate their therapeutic potential in MPNs.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC740 artigos no totalmostrando 199

2026

Improvement of psoriasis with ruxolitinib in a patient with myeloproliferative neoplasm: a therapeutic observation.

Anais brasileiros de dermatologia
2026

From Molecular Silence to Lymphoid Blast Phase: Diagnostic and Therapeutic Challenges in a Young Female Patient With Chronic Myeloid Leukemia.

Cureus
2026

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.

Transplant immunology
2026

Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.

Transfusion medicine reviews
2026

[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].

Zhonghua yi xue za zhi
2026

[Research Progress of Megakaryocyte Morphology in the Prognosis of Primary Myelofibrosis--Review].

Zhongguo shi yan xue ye xue za zhi
2026

Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.

Hematology, transfusion and cell therapy
2026

Coexistent Antiphospholipid Syndrome with Polycythemia Vera in a 25-year-old Lady Presented with Splenic Vein Thrombosis.

The Journal of the Association of Physicians of India
2026

Large PPM Lead-Associated Thrombus in a JAK2-Positive Patient.

JACC. Case reports
2026

Novel LUC7L::NUTM1 fusion in PDGFRA-rearranged myeloproliferative neoplasm with eosinophilia: a case report.

World journal of surgical oncology
2026

Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.

Circulation reports
2026

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

The Lancet. Haematology
2026

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports
2026

Ruxolitinib and heart failure outcomes among patients with myelofibrosis.

Leukemia &amp; lymphoma
2026

Case Report: Co-existence of BCR::PDGFRA gene fusion and PDGFRA variants in myeloid neoplasm with persistent leukocytosis, large splenomegaly, and eosinophilia.

Frontiers in oncology
2026

Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.

International journal of hematology
2026

Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.

British journal of haematology
2026

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.

Annals of medicine
2026

The function and molecular mechanism of HIF-1α interacted with p-STAT3 in promoting G6PD overexpression in chronic myelogenous leukemia cells.

Cellular signalling
2026

Glycolytic-inflammatory crosstalk mediated by Glyco-PMF-Rux hub genes drives PMF progression and ruxolitinib resistance.

Genes &amp; genomics
2026

Use of OCT Imaging in the Treatment of Right Coronary Artery Occlusion Causing NSTEMI as an Initial Complication of Essential Thrombocythaemia.

Case reports in cardiology
2026

The importance of bone marrow biopsy for chronic myeloid leukemia classification-a case report.

Journal of hematopathology
2026

CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.

Blood
2026

Evacuation of axillary hematoma causing brachial plexus compression in newly diagnosed leukemia: a case report and literature review.

Case reports in plastic surgery &amp; hand surgery
2026

Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2026

Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2026

Translation and Validation of Myeloproliferative Neoplasm-Symptom Assessment Form (MPN-SAF)-Total Symptom Score (MPN-SAF TSS) Filipino Version.

Acta medica Philippina
2026

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.

American journal of hematology
2026

Mechanisms of cerebral venous sinus thrombosis due to essential thrombocythemia: Current status and future perspectives.

Thrombosis research
2026

Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions.

Cancers
2026

The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.

Current hematologic malignancy reports
2026

Headache and Papilledema Unmasking an Underlying Myeloproliferative Neoplasm: A Case of Chronic Recanalized Cerebral Venous Sinus Thrombosis.

Cureus
2026

[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2026

Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis.

Cytometry. Part A : the journal of the International Society for Analytical Cytology
2026

Progress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy.

Expert opinion on investigational drugs
2026

Leukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation.

Leukemia research reports
2025

Clinical perception and novel insights of chronic myelomonocytic leukemia: a 10-year multi-center retrospective study.

Frontiers in medicine
2026

Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.

Case reports in hematology
2026

Myeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature.

World journal of clinical oncology
2026

Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report.

International journal of molecular sciences
2026

Aberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication.

Cancers
2026

Polycythemia vera and stiff-person syndrome: a case report.

BMC neurology
2026

Five-year population-based study of essential thrombocythemia in Taiwan: Epidemiology, treatment patterns, and sex-based disparities.

Journal of the Formosan Medical Association = Taiwan yi zhi
2026

Acute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report.

Annals of hematology
2026

The dual crisis of coronary thrombosis and sepsis in JAK2-mutated essential thrombocytosis: A clinical case report.

Medicine
2025

Pediatric Essential Thrombocythemia: A Case of a JAK2-Mutated Adolescent With Microvascular Symptoms.

Cureus
2026

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Annals of hematology
2026

Evaluating inflammatory markers in distinguishing polycythemia Vera from secondary polycythemia: a prospect for novel diagnostic marker.

Annals of hematology
2025

A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis.

Cancers
2026

[Diagnostic work-up of erythrocytosis].

La Revue de medecine interne
2025

[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review].

Zhongguo shi yan xue ye xue za zhi
2025

[The Research Progress of Second Cancer Onset in Myeloproliferative Neoplasms --Review].

Zhongguo shi yan xue ye xue za zhi
2026

Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.

Current opinion in hematology
2026

Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.

Cancer reports (Hoboken, N.J.)
2026

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.

Current opinion in hematology
2026

Tofacitinib Use in a Patient With Rheumatoid Arthritis and Polycythemia Vera: A Case Report.

Clinical case reports
2026

Drosophila Abi maintains blood cell homeostasis by promoting clathrin-mediated endocytosis of Notch.

The Journal of cell biology
2025

Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.

HemaSphere
2025

Noninvasive Evaluation of Chorioretinal and Peripapillary Microvascular Alterations in Essential Thrombocythemia.

Retina (Philadelphia, Pa.)
2025

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.

Cancers
2026

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial.

Hematological oncology
2025

Concurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations.

Case reports in hematology
2025

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.

Blood neoplasia
2025

Screening for an underlying myeloproliferative neoplasm in patients with chronic thromboembolic pulmonary hypertension.

Respiratory medicine and research
2025

Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression.

Annals of hematology
2025

Hemorrhagic Transformation After Ischemic Stroke in a Case of Essential Thrombocythemia with Hyperfibrinolysis on Thromboelastography.

Internal medicine (Tokyo, Japan)
2026

Myelodysplastic/Myeloproliferative Neoplasm in a Dog: A Case Report.

Veterinary medicine and science
2026

Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.

Experimental hematology
2026

Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.

Blood
2025

Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.

JCO oncology practice
2025

A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.

Cureus
2025

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.

EJHaem
2026

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Expert review of hematology
2025

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.

HemaSphere
2025

Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia.

International journal of molecular sciences
2025

Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation.

International journal of molecular sciences
2026

Integrin-dependence of extramedullary erythropoiesis in the spleen of Jak2-V617F positive myeloproliferative neoplasm in mice.

Experimental hematology
2026

Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications.

Blood reviews
2026

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

American journal of hematology
2026

Evaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera.

Journal of comparative effectiveness research
2025

Synchronous Primary Hyperparathyroidism and Polycythemia Vera: A Case Report and Literature Review.

Clinical case reports
2026

Mesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera.

Hematology, transfusion and cell therapy
2025

De Novo Myeloid Sarcoma of the Kidney: A Case Report and Literature Review of Clinical Features and Outcomes.

Cureus
2025

Macrophages in Hematopoiesis and Related Blood Diseases.

Genomics, proteomics &amp; bioinformatics
2025

Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies.

Mediators of inflammation
2025

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.

Haematologica
2025

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.

Haematologica
2025

Splenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization.

Internal medicine (Tokyo, Japan)
2025

Impaired IL-10 Receptor Signaling Leads to Inflammation Induced Exhaustion in Hematopoietic Stem Cells.

bioRxiv : the preprint server for biology
2026

Severe tophaceous gout in the setting of myelofibrosis: A clinical challenge.

Radiology case reports
2025

Prognostic utility of macrophage polarization (CD68/CD163 ratio) in Egyptian JAK2 positive myeloproliferative neoplasm patients: a single center study.

Diagnostic pathology
2025

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.

Annals of hematology
2025

Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.

Cancers
2025

The molecular management of classic myeloproliferative neoplasm.

Journal of the Egyptian National Cancer Institute
2025

Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival.

Journal of hematopathology
2025

Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: a case report.

Frontiers in oncology
2025

Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes.

World journal of clinical oncology
2025

Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.

EJHaem
2025

A Case of Myeloproliferative Neoplasm-Associated Glomerulopathy in a Patient With Myelofibrosis.

Clinical case reports
2025

Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.

Biomedicines
2025

YM155 Restores the Effect of Imatinib in Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines.

Current cancer drug targets
2025

Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib.

Thrombosis research
2025

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.

British journal of haematology
2026

Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis.

European journal of haematology
2025

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.

Acta haematologica
2025

Premature Myocardial Infarction (MI) Complicated by Cardiac Arrest Secondary to Essential Thrombocythaemia (ET).

Cureus
2025

Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion Transformed From JAK2V617F-Mutated Polycythemia Vera: A Case Report.

Cureus
2026

TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.

The American journal of medicine
2026

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

American journal of hematology
2026

Integrated one-pot RPA-CRISPR/Cas13a platform enables ultrasensitive and field-deployable JAK2 V617F detection for myeloproliferative neoplasm diagnosis.

Journal of pharmaceutical and biomedical analysis
2026

Risk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest Italy.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2025

Uncommon Evolution From Acute Myeloid Leukaemia to JAK2-Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From TET2/SRSF2-Mutated Haematopoietic Progenitors.

EJHaem
2025

Mutational Spectrum and Clinical Outcomes of Myelodysplastic/Myeloproliferative Neoplasms: A Single-Institution Study in Korea with Emphasis on U2AF1.

Journal of clinical medicine
2025

[Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

Myeloid Neoplasms with Evidence of the Additive/Cumulative Effect of Molecular Genetic Alterations That "Pave the Way" to a Specific Disease Category or Entity: Lessons Learned from Cases Submitted to the 22nd Meeting of the European Association for Haematopathology/Society of Hematopathology Bone Marrow Workshop Organized by the European Bone Marrow Working Group, Dubrovnik 2024.

Pathobiology : journal of immunopathology, molecular and cellular biology
2025

Comparison of the clinicopathological features in myeloproliferative or myelodysplastic neoplasms with SF3B1/JAK2, SF3B1/CALR, or SF3B1/MPL co-mutations.

Leukemia &amp; lymphoma
2025

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.

Current hematologic malignancy reports
2025

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Cancer
2026

Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.

Blood advances
2025

Epigenetic risk stratification in juvenile myelomonocytic leukemia by targeted methylation analysis of the BMP4 locus.

Clinical epigenetics
2025

Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.

Current hematologic malignancy reports
2025

Role and prognostic value of oncostatin M and its receptor OSMR in acute myeloid leukemia, myeloproliferative neoplasms and non-hematological malignancies.

Frontiers in oncology
2025

Midkine and TNFSF10 as downstream molecules of type I interferon are involved in the treatment of myelofibrosis.

Biochimica et biophysica acta. General subjects
2025

The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies.

Blood and lymphatic cancer : targets and therapy
2025

Hemorrhagic cardiac tamponade complicating myocardial infarction in a hemodialysis patient with essential thrombocythemia: A case report.

Medicine
2025

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Blood
2025

GPVI as a Potential New Biomarker for Myelofibrosis Diagnosis.

American journal of hematology
2025

Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis.

Annals of hematology
2025

Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera.

Leukemia research
2025

Floaters as the First Manifestation of Chronic Myeloid Leukemia: A Case Report.

International journal of molecular sciences
2025

Unveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.

International journal of molecular sciences
2025

Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.

Dermatology and therapy
2025

Metabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia.

Metabolites
2025

Different Colours of Polycythemia Vera: A Case Series.

Cureus
2026

The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.

Blood
2025

ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.

HemaSphere
2025

TYK2 is essential for the therapeutic effect of IFN-α in Jak2V617F-induced murine myeloproliferative neoplasms.

Blood neoplasia
2025

Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.

Hematology/oncology and stem cell therapy
2025

Coupling CRISPR scanning with targeted chromatin accessibility profiling using a double-stranded DNA deaminase.

Nature methods
2025

The Anti-Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies.

Food science &amp; nutrition
2025

Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report.

Frontiers in cardiovascular medicine
2025

BRAF positive Langerhans cell sarcoma arising from CALR positive myeloproliferative neoplasm: evidence of a clonal progenitor.

Virchows Archiv : an international journal of pathology
2025

Cerebral venous sinus thrombosis with head trauma and myeloproliferative neoplasm-unclassifiable: A case report.

Medicine
2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique
2025

Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis.

Tomography (Ann Arbor, Mich.)
2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique
2025

The Causal Role of the Gut Microbiota-Plasma Metabolome Axis in Myeloproliferative Neoplasm Pathogenesis: A Mendelian Randomization and Mediation Analysis.

Metabolites
2025

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Blood advances
2025

Platelet parameters and their role in myeloproliferative neoplasms, immune-mediated thrombocytopenia, and myelodysplastic syndrome.

Laboratory medicine
2025

A Case of Perioperative Management of Tongue Cancer Polycythemia Vera.

Yonago acta medica
2025

Expanding the Spectrum of CSF3R-Mutated Myeloid Neoplasm Beyond Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia: A Comprehensive Analysis of 13 Cases.

Journal of clinical medicine
2025

Unmasking systemic mastocytosis: a case of gastrointestinal involvement misdiagnosed as achalasia.

Journal of surgical case reports
2025

Leukocytoclastic Vasculitis in JAK2-Positive Essential Thrombocythemia: A Case of Cytokine-Driven Urticarial Rash Responsive to Ruxolitinib.

European journal of case reports in internal medicine
2025

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology
2025

Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.

Cancer
2025

Acquired Haemophilia A Associated With Suspected Chronic Neutrophilic Leukaemia Presenting As Fatal Retroperitoneal Haemorrhage in an Elderly Patient.

Cureus
2025

Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts.

Frontiers in oncology
2025

Palisaded Neutrophilic and Granulomatous Dermatitis Associated With ASXL1 -Mutated Chronic Myelomonocytic Leukemia: A Case Report and Literature Review.

The American Journal of dermatopathology
2025

Intersecting paths between autoimmunity and bone marrow fibrosis: the case of autoimmune myelofibrosis.

Autoimmunity reviews
2025

Landscape of somatic mutations in myeloproliferative neoplasm in Pakistani population.

Pakistan journal of medical sciences
2025

Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021.

Therapeutic advances in hematology
2025

A Rare Case of Myelofibrosis Progressing to BCR-ABL1-Positive Chronic Myeloid Leukemia With Discordant Molecular Testing.

Cureus
2025

HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.

Blood
2025

Relapse of Acute Myelogenous Leukemia With History of Myeloproliferative Neoplasm and Exacerbation of Pulmonary Hypertension.

JACC. Case reports
2025

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming.

Frontiers in oncology
2025

CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.

Journal of cellular and molecular medicine
2025

Elevated Serum Vitamin B12 Levels and Functional Vitamin B12 Deficiency among Patients with Myeloproliferative Neoplasms.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2025

Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.

Journal of inflammation research
2025

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Annals of hematology
2025

Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.

JCO oncology practice
2025

Defying the Odds: Small Cell Lung Cancer with Essential Thrombocythemia and Secondary Cancers.

Cureus
2025

Novel insights into the ULK2-FIP200-AMPK-mediated regulation of autophagy and BCR::ABL degradation in chronic myeloid leukemia.

Biochemical and biophysical research communications
2025

Pulmonary Artery Thromboembolism as a Complication of Essential Thrombocythemia.

Cureus
2025

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.

Acta haematologica
2025

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression.

Blood
2025

Case Report of Hepatic Sinusoidal Obstruction Syndrome Complicated with Myeloproliferative Neoplasm and Focal Segmental Glomerulosclerosis.

Case reports in gastroenterology
2025

A comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey.

BMC cancer
2025

Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells.

Discover oncology
2025

Bleeding Complications in JAK2-Variant Essential Thrombocythemia: A Revisit in 2025.

EJHaem
2025

[Avapritinib for systemic mastocytosis with an associated myelodysplastic/myeloproliferative neoplasm: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.

Acta haematologica
2025

Bone Marrow Basophil Evaluation in Myeloproliferative Neoplasms Using Flow Cytometry.

International journal of laboratory hematology
2025

Contemporary CMML Risk Stratification and Management.

Current hematologic malignancy reports
2025

Rare manifestations of pediatric chronic myeloid leukemia: a case report on priapism and a literature Review.

Frontiers in oncology
2025

Autophagosome-lysosome mediated secretion of the thrombopoietin receptor is modulated by distinct driver mutations of myeloproliferative neoplasm.

Leukemia
2025

Latent JAK2 V617F-Positive Myeloproliferative Neoplasm With Normal Blood Counts and Recurrent Splanchnic Vein Thrombosis in a Young Woman.

Cureus
2025

Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.

European journal of haematology
2025

CALR Type 1-Like Mutations Increase Endoplasmic Reticulum Free Ca2+ and Induce ERK1/2 Activation Independent of Thrombopoietin Receptor Activation.

Cell biology international
2025

Comparison of ELTS Score with Sokal, Euro and EUTOS Scores in Risk Stratification of Patients with Chronic Myeloid Leukaemia at a Tertiary Care Hospital in Bangladesh.

Mymensingh medical journal : MMJ
2025

CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study.

Medicina (Kaunas, Lithuania)
2025

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence.

Bioengineering (Basel, Switzerland)
2025

Intermediate-Dose Cytarabine as Postinduction AML Therapy.

NEJM evidence
2024

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis.

Blood neoplasia
2025

AML1-ETO and CCND2 overexpression cooperate to drive acute myeloid leukemia initiation and progression.

Journal of leukocyte biology
2025

A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis.

Leukemia research
2025

Treatment patterns and blood count control in 10,112 patients with polycythemia vera.

Expert review of hematology
2025

A Rare Case of Chronic Myelomonocytic Leukemia in a Patient With Sarcoidosis: Diagnostic and Immunologic Challenges.

Cureus
2025

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms.

Translational oncology
2025

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.

Nature genetics
Ver todos os 740 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença mieloproliferativa crônica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença mieloproliferativa crônica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.
    Hematology, transfusion and cell therapy· 2026· PMID 41825406mais citado
  2. Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.
    Circulation reports· 2026· PMID 41808951mais citado
  3. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.
    The Lancet. Haematology· 2026· PMID 41791832mais citado
  4. The function and molecular mechanism of HIF-1&#x3b1; interacted with p-STAT3 in promoting G6PD overexpression in chronic myelogenous leukemia cells.
    Cellular signalling· 2026· PMID 41759798mais citado
  5. Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms.
    Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion· 2026· PMID 41728173mais citado
  6. Case Report: The diagnostic and therapeutic crossroads: when myelofibrosis transforms into mixed phenotype acute leukemia.
    Front Oncol· 2026· PMID 41988126recente
  7. Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia.
    J Hematol· 2026· PMID 41983157recente
  8. Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.
    Leuk Lymphoma· 2026· PMID 41982071recente
  9. Myeloproliferative neoplasm as a cause of splanchnic vein thrombosis.
    BMJ Case Rep· 2026· PMID 41980793recente
  10. Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?
    Expert Rev Hematol· 2026· PMID 41978336recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98274(Orphanet)
  2. MONDO:0020076(MONDO)
  3. GARD:9319(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18555039(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença mieloproliferativa crônica
Compêndio · Raras BR

Doença mieloproliferativa crônica

ORPHA:98274 · MONDO:0020076
Prevalência
1-9 / 100 000
CID-10
D47.1 · Doença mieloproliferativa crônica
Ensaios
15 ativos
Início
All ages
Prevalência
3.07 (Europe)
MedGen
UMLS
C1292778
Repurposing
1 candidato
anagrelidephosphodiesterase inhibitor
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades